Fresenius secures exclusive options on up to 37 WuXi Biologics biosimilar candidates over ten years
- Fresenius and WuXi Biologics signed an exclusive development agreement on 2 November 2026.
- Fresenius gets option rights to as many as 37 biosimilar candidates over the next decade, spanning 13 therapeutic areas. That could lift its portfolio from 29 molecules to up to 66.
- WuXi is paid fee-for-service for each candidate Fresenius selects. Fresenius keeps global commercialization rights and the full economics.
- Fresenius says the deal is funded from operating cash flow, with no new financing and 2026 guidance and 2030 targets unchanged.
💡 Points Based on public reports
Is this an option or a pipeline? Fresenius pays only for candidates it picks, while WuXi carries development risk upfront for fee-for-service income, so the economics skew toward Fresenius. Growing from 29 to up to 66 molecules is ambitious against biosimilar price erosion; watch which targets get exercised first, and whether US biosecurity scrutiny of WuXi intrudes.
WuXi Biologics, Fresenius partner ahead of biosimilar boom ↗